New findings from Karolinska Institutet reveal how the gene HNRNPU coordinates several fundamental molecular processes during the earliest stages of human brain development. The study is published in ...

Antiphospholipid syndrome, also known as APS, is an autoimmune disease that sits at the intersection of inflammation and blood clotting. Antiphospholipid syndrome is best known for increasing the risk ...

Here’s how extinct DNA could help us in the present—and the future. Yeah, we know—it’s not a dire wolf. In early 2025, the Texas biotech company Colossal Biosciences landed with a splash on the cover ...

I hate to break this to you, but every child is a genetic experiment – and nature doesn’t care if things go wrong. Our genomes are awful messes created by conflicting evolutionary forces, and every ...

This year marked a pivotal moment in the quest to treat Huntington’s disease, a rare but devastating form of dementia. Scientists found that an experimental gene therapy slowed the condition’s ...

Northwestern Medicine scientists have discovered how molecular "traffic controllers" in cells influence aging and cellular senescence—a state where cells stop dividing but remain metabolically active.

KJ Muldoon received a groundbreaking new treatment earlier this year. The baby saved from a rare disease by a first-ever personalized gene fix has reached a big milestone, taking his first steps ahead ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College of Medicine and the UMass Chan Medical School have achieved ...

In a breakthrough study, scientists have discovered that a variant in one gene, GRIN2A, can directly cause mental illness – something previously believed to be the result of several mutations working ...

With a new study in the journal Cell, researchers at Stanford University and Stockholm University have contributed to increased knowledge about gene regulation in human cells. How genes are turned on ...

Nov 24 (Reuters) - (This Nov 24 story has been corrected to fix the pricing for Zolgensma to $2.5 million from $2.1 million in paragraph 4) The U.S. Food and Drug Administration has approved Novartis' ...

Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases. By Pam Belluck and Carl Zimmer Gene-editing therapies offer ...